Riskpilot← Back to searchSign inGet full accessDiProServa Medical AB
ABActiveOrg 5566996178Adelgatan 21Research and experimental development on natural sciences and engineering · NACE 7210Est. 20060 employees
Revenue 2024
SEK 19,9M
+4% vs 2023
EBITDA margin
68.6%
+11% vs 2023
Equity ratio
42.1%
Financial strength
Net profit 2024
SEK 9,1M
+18% vs 2023
| Revenue | SEK 19,9M | +4% |
| EBITDA | SEK 13,7M | +11% |
| Net profit | SEK 9,1M | +18% |
| Total assets | SEK 82,8M | +31% |
| Equity | SEK 34,8M | +36% |
| Employees | 0 | — |
Legal name
DiProServa Medical AB
Org number
5566996178
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
15 mars 2006
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna externa firmatecknarna
Company purpose
Bolagets verksamhet är att utveckla, dokumentera, tillverka och kommersialisera produkter inom medicin och bioteknik samt idka därmed förenlig verksamhet.
Address
Adelgatan 21
Phone
+46406992515
Email
ea@diproserva.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 12 229 | 16 190 | 17 757 | 19 096 | 19 938 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 8 309 | 11 110 | 12 121 | 12 349 | 13 674 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 8 309 | 11 110 | 12 121 | 12 349 | 13 674 |
| Net financials | −92 | −70 | −21 | −1 | −2 |
| Profit before tax | 6 155 | 0 | 6 930 | 9 803 | 11 619 |
| Tax | −1 324 | −9 | −1 451 | −2 064 | −2 478 |
| Net profit | 4 831 | −9 | 5 479 | 7 739 | 9 141 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 24 629 | 32 250 | 45 255 | 63 375 | 82 752 |
| Equity | 12 472 | 12 463 | 17 942 | 25 681 | 34 823 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 866 | 12 596 | 18 953 | 26 788 | 34 970 |
| Total debt | 4 866 | 12 596 | 18 953 | 26 788 | 34 970 |
EBITDA margin
68.6%
This company
15.8%
Market median
+334% vs market
20202024
Equity ratio
42.1%
This company
38.2%
Market median
+10% vs market
20202024
Return on equity
26.2%
This company
18.4%
Market median
+42% vs market
20202024
Net profit margin
45.8%
This company
8.1%
Market median
+465% vs market
20202024
Asset turnover
0.24×
This company
1.12×
Market median
-79% vs market
20202024
Debt / equity
1.38×
This company
0.62×
Market median
-123% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
KK External Signatory | External Signatory | 2024 |
PW Chief Auditor | Chief Auditor | 2025 |
EH External Signatory | External Signatory | 2020 |
RA External Signatory | External Signatory | 2024 |
CM Authorized Recipient of Service | Authorized Recipient of Service | 2022 |
JC External Signatory | External Signatory | 2020 |
| Former (2) | ||
AF External Signatory | External Signatory | 2020 – 2022 |
PÅ Chief Auditor | Chief Auditor | 2020 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2020 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Former (4) | ||
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2020 – 2020 | |
| Chairman | 2020 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
FRIDABABY, LLC
DiProServa Medical AB Board members of DiProServa Medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kathryn Klug Alexander | External Signatory | 0 companies |
| Patrik Wajnsztajn | Chief Auditor | 0 companies |
| Alyssa Fernandez-Isla | External Signatory | 0 companies |
| Per Åke Joakim Stomberg | Chief Auditor | 0 companies |
| Eric Hirschhorn | External Signatory | 0 companies |
| Robert Andrew Karpf | External Signatory | 0 companies |
| Carl Magnus Svernlöv | Authorized Recipient of Service | 0 companies |
| Jennifer Carmen Greenberg | External Signatory | 0 companies |
| Jessica Thörnestad | Board of Directors | 0 companies |
| Christian Rahmig | Board of Directors | 0 companies |
| Marco Sparesato | Board of Directors | 0 companies |
| Carl-Axel Benjamin Åfors | Board of Directors | 0 companies |
| Alexandra Laurell | Board of Directors | 0 companies |
| Eric Robert Kutsenda | Chairman | 0 companies |
| Chelsea Maren Hirschhorn | Chairman | 0 companies |